TWiV 910: COVID-19 clinical update #119 with Dr. Daniel Griffin
Jun 18, 2022•47 min•Ep. 910
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
In COVID-19 clinical update #119, Dr. Griffin reviews tixagevimab for infection prevention, ivermectin for outpatient infection treatment, symptom rebound after PAXLOVID treatment, bamlanivimab minimally impacting immune response to vaccination, in-hospital mortality among infection patients, residual viral antigen in patients following infection, usage of Casirvimab/Imdevimab and Remdesivir in infected patients with depleted B-cells, and rheumatic symptoms following infection.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode- Tixagevimab-Cilgavimab for infection prevention (NEJM)
- Ivermectin for outpatient infection treatment (medRxiv)
- Symptom rebound after PAXLOVID treatment (IDSA)
- Bamlanivimab minimally impacts immune response to vaccination (Sci Transl Med)
- In-hospital morality among infected patients (IDSA)
- Casirvimab/Imdevimab & Remdesivir for infected B-cell depleted patients (IDSA)
- PAXLOVID patient eligibility screening checklist (FDA)
- Remdesivir fact sheet for providers (Veklury)
- Bebtelovimab fact sheet for providers (FDA)
- Residual viral antigen in patients post infection (IDSA)
- Rheumatic symptoms following infection (IDSA)
- Contribute to FIMRC fundraiser at PWB
- Dr. Griffin's treatment guide (pdf)
- Letters read on TWiV 910
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv
For the best experience, listen in Metacast app for iOS or Android